Build status - In Progress

A Clinical Study of NLY01 in Patient's With Early Parkinson's Disease

A Clinical Study of NLY01 in Patient's With Early Parkinson's Disease
Recruiting
30 years - 80 years
All
Phase 2
4 participants needed
1 Location

Brief description of study

This is a study designed to assess the safety, tolerability and efficacy of NLY01 in subjects with early untreated Parkinson's disease (PD). Evidence suggests NLY01, a pegylated form of exenatide, may be beneficial in Parkinson's disease and is being developed as a potential treatment for neurodegenerative disorders.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Parkinson's Disease
  • Age: 30 years - 80 years
  • Gender: All

Male or Female, Age 30-80, Diagnosed with Parkinson's disease

Updated on 04 Aug 2024. Study ID: 842594

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center